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Abstract
Background: During the pathological destruction of lung tissue, neutrophil elastase (NE) degrades elastin, one of the
major constituents of lung parenchyma. However there are no non-invasive methods to quantify NE degradation of
elastin. We selected specific elastin fragments generated by NE for antibody generation and developed an ELISA assay
(EL-NE) for the quantification of NE-degraded elastin.
Methods: Monoclonal antibodies were developed against 10 NE-specific cleavage sites on elastin. One EL-NE assay
was tested for analyte stability, linearity and intra- and inter-assay variation. The NE specificity was demonstrated using
elastin cleaved in vitro with matrix metalloproteinases (MMPs), cathepsin G (CatG), NE and intact elastin. Clinical relevance
was assessed by measuring levels of NE-generated elastin fragments in serum of patients diagnosed with idiopathic
pulmonary fibrosis (IPF, n = 10) or lung cancer (n = 40).
Results: Analyte recovery of EL-NE for human serum was between 85% and 104%, the analyte was stable for four
freeze/thaw cycles and after 24 h storage at 4°C. EL-NE was specific for NE-degraded elastin. Levels of NE-generated
elastin fragments for elastin incubated in the presence of NE were 900% to 4700% higher than those seen with CatG
or MMP incubation or in intact elastin. Serum levels of NE-generated elastin fragments were significantly increased in
patients with IPF (137%, p = 0.002) and in patients with lung cancer (510%, p < 0.001) compared with age- and
sex-matched controls.
Conclusions: The EL-NE assay was specific for NE-degraded elastin. The EL-NE assay was able to specifically quantify
NE-degraded elastin in serum. Serum levels of NE-degraded elastin might be used to detect excessive lung tissue
degradation in lung cancer and IPF.
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Background
The common denominator of several lung diseases is
massive lung extracellular matrix (ECM) remodeling [1].
Lung diseases with increased lung tissue turnover
include idiopathic pulmonary fibrosis (IPF) and lung
cancer [2,3]. Protease-mediated degradation of the lung
ECM is a well documented and a significant part of lung
tissue degradation [1,4]. Many of the responsible proteases,
neutrophils in particular, are associated with lung diseases
such as IPF and lung cancer [5,6].
One of the signature proteins of the lungs is elastin.
Elastin provides resilience and elasticity to the lungs [7,8].
Neutrophil elastases (NEs) are produced by neutrophils
[9] and are able to degrade the otherwise stable elastin
fibers in the lung [10]. NE expression and activity levels
have for some time been coupled with chronic obstructive
pulmonary disease (COPD). Neutrophil levels identified in
the sputum of patients diagnosed with COPD have been
shown to be elevated compared with controls [9]. In
alignment, an increase in neutrophil cell count and cell
percentage was observed in bronchoalveolar fluid (BALF)
from patients with IPF compared with controls [5].
Furthermore NE may play a destructive role in lung
cancer especially non-small-cell lung cancer subtypes such
as squamous cell carcinoma and adenocarcinoma [11].
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The aim of this study was to identify and quantify
NE-generated elastin degradation, and assess the relation-
ship between levels of elastin fragments and pulmonary
disorders such as lung cancer and IPF that involve
excessive lung tissue remodeling. We selected unique
fragments of elastin degraded specifically by NE, developed
a novel ELISA assay detecting exclusively NE-degraded
elastin and investigated NE activity towards elastin in lung
cancer and IPF.
Methods
Selection of peptides for immunizations
Decapeptides at the N- or C-terminus of known NE
cleavage sites on elastin [10] were considered candidate
immunogens. The decapeptides were selected for their
distance to other known elastase cleavage sites in the
primary structure of elastin [10,12]. Cleavage sites furthest
away from other cleavage sites were preferred and the
final number of candidates was reduced to 10. Selected
decapeptide sequences were screened for theoretical
cleavage sites of trypsin and chymotrypsin as well as to
the cleavage sites from in-house human elastin degradome
database obtained from previous study [13]. Selected
decapeptides were blasted for homology to decapeptide
sequences from other proteins using the NPS@: network
protein sequence analysis with the UniProt/Swiss-Prot
database [14]. A total of 60 mice were immunized, with
groups of six mice each being immunized with a single
immunogen.
Immunization procedure
The immunization [13] and fusion procedures [15] have
been described elsewhere. To create the EL-NE assay
immunogen, the immunogen (CGG-GGPGFGPGVV,
Chinese Peptide Company, Beijing, China) was coupled
to the Keyhole limpet hemocyanin (KLH) carrier protein
using Succinimidyl-4-(N-maleimidomethyl)cyclohexane-
1-carboxylate (SMCC, Thermo Scientific, Waltham, MA,
USA) as the linker. The adjuvant used was Freund’s
incomplete adjuvant (Sigma-Aldrich, St. Louis, MO, USA)
Characterization and selection of antibodies
Native reactivity and peptide binding of the generated
monoclonal antibodies were validated by displacement
of human serum in a preliminary indirect ELISA using
biotinylated peptides (Biotin-KK-GGPGFGPGVV for
EL-NE) on a streptavidin-coated microtitre plate (Roche,
Basel, Switzerland) and the supernatant from the
monoclonal hybridoma. The clones were characterized
by testing the reactivity of their supernatant to the
free peptide (GGPGFGPGVV for EL-NE), the elongated
peptide (GGPGFGPGVVG for EL-NE) and a nonsense
peptide (VGAGVPGLGV for EL-NE). The selected
clones were purified using Protein G columns according
to manufacturer’s instructions (GE Healthcare Life Science,
Little Chalfont, Buckinghamshire, UK). All peptides were
produced by the Chinese Peptide Company (Beijing,
China). The final selection of the monoclonal antibody for
assay development was based on high reactivity towards its
free peptide and towards serum samples from patients
diagnosed with IPF (ProteoGenex, Culver City, CA, USA)
combined with low reactivity towards their elongated
peptide and intact elastin. Peptide sequences for applied
peptides were confirmed with mass spectrometry by the
peptide company (Chinese Peptide Company, Beijing,
China) after synthesis.
EL-NE protocol
The selected monoclonal antibody was inserted into com-
petitive ELISA systems and labeled with horseradish
peroxidase (HRP) using the Lightning link HRP labeling
kit according to the instructions of the manufacturer (cat.
no.701-003 Innova Bioscience, Babraham, Cambridge, UK).
A 96-well streptavidin plate was coated with 5 ng/mL
screening peptide (Biotin-KK-GGPGFGPGVV for EL-NE)
dissolved in coater buffer (10 mM PBS, 1% BSA, 0.1%
Tween-20, pH 7.4, 8 g/L NaCl) and incubated for
30 minutes at 20°C. 20 μL of free peptide calibrator
or sample were added in duplicate to appropriate
wells, followed by 100 μL of conjugated monoclonal
antibody in assay buffer (25 mM PBS, 1% BSA, 0.1%
Tween-20, pH 7.4, 2 g/L NaCl) and incubated for 3 hours
at 4°C. After each incubation step the plate was washed
five times in washing buffer (20 mM Tris, 50 mM NaCl,
pH 7.2). Finally, 100 μL tetramethylbenzinidine (TMB,
Kem-En-Tec Nordic, Taastrup, Denmark) was added and
the plate was incubated for 15 minutes at 20°C in the dark.
All the above incubation steps included shaking at
300 rpm. The TMB reaction was stopped by adding 100 μL
of stopping solution (1% H2SO4) and optical density was
measured at 450 nm with 650 nm as the reference.
Technical validation of EL-NE
From 2-fold dilutions of human samples of serum and
plasma citrate and heparin, linearity was calculated as a
percentage of recovery of the undiluted neoepitope. The
lower limit of detection was determined from 21 zero
samples (assay buffer) and calculated as the mean + 3X
standard deviation. The lower limit of quantification was
determined as the highest level of NE-generated elastin
fragments with coefficient of variation (CV) below 30%
reproduced in serum samples. The inter- and intra-assay
variation was determined by 10 independent runs of 8
samples that covered the detection range of the EL-NE.
Besides five human serum samples, the 8 samples included
one bovine serum sample, one sample with the free peptide
in human serum and one sample with the free peptide
in buffer. The freeze-thaw recovery of human serum
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and citrate and heparin plasma was determined by
measuring the NE-degraded levels of elastin in three
samples of each, which were exposed to four freeze-thaw
cycles and compared to NE-generated levels of elastin
prior to the first cycle. Analyte stability was determined by
the levels of NE-degraded elastin in three samples each of
human serum and plasma citrate and heparin after either
4°C or 20°C storage for 24 hours and compared with the
levels at zero hours.
EL-NE specificity
The reactivity of the EL-NE antibody towards the free
peptide (GGPGFGPGVV) was compared with its reactivity
to the elongated peptide (GGPGFGPGVVG), a nonsense
peptide (VGAGVPGLGV) as well as to the free peptide
where a nonsense peptide was applied as screening peptide
(VGAGVPGLGV-KK-Biotin). The added peptide doses
were 119 nM, 59 nM, 30 nM, 15 nM, 7 nM, 4 nM, 2nM
and 0 nM.
Levels of NE-degraded elastin were determined in the
presence of elastin in vitro cleaved with: matrix metallo-
proteinase (MMP)-2, MMP-7, MMP-9, MMP-12 or NE,
NE in NE buffer as well as intact elastin dissolved in NE
buffer (all incubated for 48 hours at 37°C). Elastin was
incubated once with each enzyme. Enzyme:protein ratios
were 1:100 (MMPs) or 1:200 (NE) (weight/weight). For
cross-reactivity towards CatG cleavage, enzyme:protein
ratios were 1:50 (NE) and 1:15 (CatG) (weight/weight).
Incubation times for the cleavages, intact elastin, NE and
CatG were 24 hours at 37°C. Activity tests were performed
on proteases prior to cleavage. All material was diluted
100x in assay buffer before measurement. Insoluble elastin
was purchased from Sigma-Aldrich (cat. no. E6777, St.
Louis, MO, USA); MMP-2 and MMP-9 from Calbiochem
(cat. no. 444213 and 444231, Whitehouse Station, NJ,
USA), MMP-7 and MMP-12 from R&D Systems (cat. no.
907-MP-010 and 917-MP-010, Minneapolis, MN, USA),
cathepsin G from Elastin Product Company (cat. No.
SG623, Owensville, MO, USA) and NE from Abcam
(cat. no. ab80475, Cambridge, UK).
Clinical validation of EL-NE
Levels of NE-degraded elastin were determined in serum
from patients diagnosed with IPF (n = 10, mean age
74 years, 20% female) and compared with healthy age- and
sex-matched controls (n = 9, mean age 72 years, 22%
female). NE-generated elastin levels were also measured in
serum from patients diagnosed with lung cancer (n = 40, of
which n = 16 had squamous cell carcinoma, n = 16 had
adenocarcinoma, n = 8 had small cell lung cancer; mean
age 59 years, 25% female) and compared with healthy
age- and sex-matched controls (n = 12, mean age 60 years,
25% female). All controls were derived from a previously
described study [16]. Patient samples were obtained from
the commercial vendor Proteogenex (Culver City, CA).
After signed consent from patients and approval by the
appropriate Institutional Review Board or Independent
Ethical Committee, serum had been collected from
patients with IPF or lung cancer. According to Danish
law, it is not required to obtain ethical approval when
measuring biochemical markers in previously collected
samples; hence, there was no additional ethical approval
for this study. Samples were all collected, processed, and
stored in a similar fashion until analyzed. Patient samples
were collected prior to surgery. Additional patient demo-
graphics and clinical information is presented in table S1
(see Additional file 1: Appendix 1).
Statistical analyses
The geometric means (95% CI) of serum levels of
NE-generated elastin fragments in diagnosed patients
were compared with their respective controls using
the two-sided non-parametric Mann Whitney test. All
statistical analyses were performed in MedCalc from
MedCalc Software (Ostend, Belgium). Results were
considered statistically significant if p < 0.05.
Detailed materials and methods for the EL-NE-B
competitive ELISA (VGAGVPGLGV) can be seen in
Additional file 2: Appendix 1.
Results
Selection, reactivity, specificity and technical validation of
the EL-NE assay
The EL-NE sequence (GGPGFGPGVV) was unique in
the human proteome with homology to human elastin
[UniProt:P15502] only. Ten decapeptides were selected
for immunization after the homology search, from which
a total of 60 antibodies were developed. The EL-NE anti-
body was selected due to its high reactivity towards free
peptide, elastin cleaved with NE and serum from patients
diagnosed with IPF and lung cancer, combined with a low
reactivity towards the elongated peptide, intact elastin as
well as elastin cleaved with MMPs. Results from a different
decapeptide immunogen candidate, EL-NE-B, are shown in
Additional file 2: Appendix 2, Figure S1 and Figure S2.
The inhibition of the EL-NE monoclonal antibody in a
competitive ELISA assay with the free-, elongated- and
nonsense peptide and nonsense screening peptide is pre-
sented in Figure 1A. The EL-NE monoclonal antibody
could be inhibited by the free peptide by 91% but was not
significantly inhibited by the elongated- (3%) and nonsense
peptide (5%). There was no reactivity between the
nonsense screening peptide and the EL-NE antibody.
Levels of NE-degraded elastin were assessed in the pres-
ence of human elastin cleaved in vitro by MMP-2, −7, −9,
−12, NE (48 hours) and non-cleaved elastin as well as
NE in NE buffer without elastin (Figure 1B). Levels of
NE-degraded elastin fragments of elastin incubated in
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the presence of NE were 2239%, 3168%, 4011%,
2576%, 4709% and 908% higher than elastin incubated
without proteases, NE alone, elastin incubated in the
presence of MMP-2, MMP-7, MMP-9 and MMP-12
respectively. Levels of elastin in vitro cleaved with NE
were also compared with Cat-G cleavage of elastin and
intact Cat-G (Figure 2). NE-degraded levels of elastin
in the presence of the Cat-G, NE enzymes alone and
intact elastin after 24 hours incubation were below
the lower limit of detection of the assay. Levels of
NE-degraded elastin in elastin incubated with NE
were 2002% higher than elastin incubated with Cat-G.
Following the selection of EL-NE as a suitable assay, a
range of validation tests were performed. The technical
validation data for EL-NE is listed in Table 1. EL-NE has
a lower limit of detection and quantification of 0.90 nM
and 1.9 nM respectively. For human serum, heparin
and citrate plasma the EL-NE neoepitope had an analyte
recovery percentage of 85% to 104%. The analyte recovery
results included samples diluted in assay buffer, samples
subjected to four freeze/thaw cycles and samples stored at
4°C for 24 hours. Recovery after 24 hours storage at 20°C
was 77% and is not regarded as acceptable, as the limit is
80%. The variation in levels of NE-generated elastin
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Figure 1 Characterization and Specificity of the EL-NE Monoclonal Antibody. (A): Competitive ELISA showing inhibition of free peptide
(GGPGFGPGVV), elongated peptide (GGPGFGPGVVG), nonsense peptide (VGAGVPGLGV) and nonsense screening peptide (Biotin-KK- VGAGVPGLGV).
(B): EL-NE fragment levels after 48 hours in vitro incubation of intact human elastin separately in buffer (ELN), elastin incubated in the presence of NE,
MMP-2, MMP-7, MMP-9 and MMP-12. NE incubated for 48 hours separately in buffer was added as control. Abbreviations: ELN, elastin; NE, Neutrophil
elastase; MMP, matrix metalloproteinase.
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Figure 2 Cross-Reactivity to Cathepsin. EL-NE fragment levels after
24 hours in vitro incubation of intact human elastin separately in
buffer (ELN) and elastin incubated with CatG and NE. EL-NE levels
in NE and CatG separately in buffer are also shown. Abbreviations:
ELN, elastin; NE, Neutrophil elastase; CatG, Cathepsin G.
Table 1 Technical validation of the EL-NE assay
Technical validation step EL-NE
Detection range 0.90 nM – 119 nM
Lower limit of quantification 1.9 nM
Intra-assay variation 7%
Inter-assay variation 11%
Dilution range of serum samples 1:2 (recommended)
Dilution range of plasma samples 1:2 (recommended)
Dilution recovery in serum 104%
Dilution recovery in plasma (Heparin) 86%
Dilution recovery in plasma (Citrate) 108%
Freeze-thaw recovery in serum 96%
Freeze-thaw recovery in plasma (Heparin) 87%
Freeze-thaw recovery in plasma (Citrate) 104%
Analyte stability serum (24 h, 4°C/20°C) 88%/77%
Analyte stability plasma (Heparin) (24 h, 4°C/20°C) 95%/111%
Analyte stability plasma (Citrate) (24 h, 4°C/20°C) 85%/77%
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fragments in eight different samples during 10 separate
runs was 11% with a 7% intra-assay variation per run.
NE elastin activity is increased during excessive lung
remodeling
Mean serum levels of NE-degraded elastin were 137%
higher in IPF patients (5.4 nM) than in controls (2.3 nM,
p =0.002, Figure 3A). Mean levels of NE-generated
elastin were 510% higher in serum from patients diag-
nosed with lung cancer (12.6 nM) than in controls
(2.1 nM p < 0.0001, Figure 3B). Analysis by cancer subtypes
showed NE-degraded elastin levels were 607% higher in
squamous cell carcinoma (14.6 nM), 481% higher in
adenocarcinoma (12.0 nM) and 402% higher in small cell
lung cancer (10.3 nM) than in healthy matched controls.
The EL-NE-B assay did not show elevated NE-generated
levels of elastin in IPF (see Additional file 2, Appendix 2:
Figure S2A) although it demonstrated high specificity
towards its free peptide and elastin cleaved with NE. The
EL-NE-B program however was thereafter terminated.
Discussion
To our knowledge this is the first quantification of an
NE-generated elastin fragment in human serum. The
main findings of this study were: 1) the selection and
quantification of a unique NE-generated elastin fragment;
2) development of the EL-NE antibody which was specific
towards a NE cleavage site on elastin and not towards
other proteases; 3) development of a competitive ELISA
assay for the assessment of NE-degraded elastin in serum;
4) demonstration that levels of NE-degraded elastin were
significantly elevated in serum from IPF and lung cancer
patients compared with healthy controls.
Selection of the EL-NE assay
The antibody for the EL-NE assay was selected from a
total of 60 antibodies. Besides that used in the EL-NE
assay, other promising antibodies were developed
towards NE-specific degraded elastin. As an example
EL-NE-B (see Additional file 2) demonstrated high
specificity towards its free peptide and elastin cleaved with
NE. However the clinical relevance of EL-NE-B was low as
it could not discriminate between IPF and healthy controls.
Furthermore, using the EL-NE-B assay, NE-degraded
elastin was only detectable in very low levels in serum from
healthy and diseased patients.
Technical validation and specificity of EL-NE
The low inhibition by the elongated peptide demon-
strated that the antibody only recognizes the neoepitope
occurring after proteolytic cleavage between Val334 and
Gly335. The high levels of the EL-NE fragment in elastin
cleaved in vitro with NE, compared with MMPs or
Cat-G, demonstrated that the EL-NE assay is specific
for NE-degraded elastin and that the EL-NE fragment
is not a total protein marker since reactivity with
intact elastin was minimal. The selected NE cleavage site
on elastin is not adjacent to common proteases such as
trypsin or chymotrypsin. The levels of the elastin fragment
could be recovered after four freeze/thaw cycles and
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Figure 3 Degradation of Elastin in IPF and lung cancer. (A): EL-NE fragment levels in serum from patients with IPF (n = 10) compared with
controls (n = 9). ** p < 0.01. (B): EL-NE fragment levels in serum from patients diagnosed with lung cancer (n = 40 in total), SCC (n = 16),
adenocarcinoma (n = 16) and SCLC (n = 8) compared with controls (n = 12). **** p < 0.0001. Groups were compared by T-test with Welch
correction. Data are shown as the geometric mean (95% CI). Abbreviations: IPF, idiopathic pulmonary fibrosis; SCC, squamous cell carcinoma; SCLC,
small cell lung carcinoma.
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24 hours storage and the NE-degraded elastin levels
decreased in proportion to the number of times samples
were diluted. Thus we developed an assay that quantifies a
specific NE-derived elastin fragment.
When quantifying the effectiveness of NE inhibitors in
pulmonary studies the determination of NE activity
often includes the isolation of neutrophils, mainly from
the blood [17]. After addition of substrates, such as
methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide the NE
activity can be quantified. The development and production
of NE substrates are considerably faster than monoclonal
antibodies. However, the EL-NE assay does not depend on
cell extraction and can be applied directly to serum
samples. Cell and protease extraction is a significant
source of variation and the process may affect NE
activity. As demonstrated in this study, the EL-NE
assay may recover the majority of analytes after a
series of freeze/thaw cycles and storage above freezing
temperatures. It is questionable whether ECM proteases
stored in serum could maintain the majority of their activity
during freeze/thaw cycles.
Neutrophil elastase activity in IPF
The increased levels of NE-degraded elastin in IPF patient
samples indicated that NE-specific degradation of elastin
may have a relevant diagnostic role within IPF. In IPF the
role of MMPs has received much focus [5,18] but NE
activity in IPF can also be an indicator of survival rate [5].
The EL-NE IPF data corresponds well with the discovery
that IPF patients with a low BALF neutrophil cell percent-
age were more likely to survive than IPF patients with a
higher percentage [5,19]. The increase in neutrophils in
IPF patients may explain the higher levels of circulating
elastin fragments in IPF patients compared with controls.
EL-NE fragment levels of 2 nM in the controls may be
caused by background ECM remodeling combined with
matrix effects from the serum. Further studies with control
and patient samples obtained with identical standard
operating procedures are needed to investigate elastin frag-
ment levels in healthy controls. As the formation of elastin
mostly occurs during the younger years increased levels of
NE-degraded elastin fragments may be an indicator of
imbalanced tissue remodeling, a significant contributor to
IPF, in adults. Larger longitudinal studies may reveal the
prognostic potential for the EL-NE assay in IPF.
NE activity in lung cancer
Elevated levels of NE have been coupled with cancer
invasion and metastasis in lung cancer [6,11] and most
likely explains the increased levels of NE-generated elastin
fragments in lung cancer patients. High NE proteolytic
activity on elastin may therefore be related to the ex-
cessive ECM turnover observed during the progression
of lung cancer.
Limitations
All clinical samples were collected in cross-sectional
studies. Longitudinal studies, with several time points and
a larger representation of varying disease severity would
enable a better description of NE-degraded elastin as a
marker of excessive ECM lung turnover. Controls were not
matched according to race or smoking history and
were collected at different centers than the disease
samples. The clinical validation of EL-NE was per-
formed in serum. Future studies should include BALF
and plasma samples.
Conclusions
In conclusion we have utilized specific NE-elastin cleavage
sites to develop a non-invasive ELISA assay (EL-NE) to
assess levels of NE-generated elastin fragments. The
EL-NE analyte can be recovered after dilution, freeze/
thaw cycles and temporary storage above freezing
temperature. The developed EL-NE assay was specific
towards elastin cleaved in vitro with NE. We conclude
that the quantification of the EL-NE analyte may be a
marker of the increased tissue remodeling observed in
pulmonary disorders such as IPF and lung cancer.
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